IN FOCUS
955 Spotlight on the September 4 Issue
1001 This Week’s Neurology® Podcast

SPECIAL EDITORIAL
956 The Neurology® Podcast: 2007–2012: Can you hear me now?
S.A. Moriarity and T.M. Burns

EDITORIALS
958 Risk stratification in TIA patients: “It’s the vascular lesion, stupid!”
J.A. Edlow
960 Stroke symptoms signal worse outcomes in patients with end-stage renal disease
K. Kalantari and S. Seliger
962 FTD/ALS families are no longer orphaned: The C9ORF72 story
J.C. van Swieten and M. Grossman
965 Sporadic Creutzfeldt-Jakob disease: Changes not only in the brain?
B.S. Appleby and I. Zerr
967 Learning standardized sign-outs: Handoff help just in time!
G.R. Finney and S. Martin-Schild

IN MEMORIAM
969 C. Miller Fisher, MD (1913–2012)
W.J. Koroshetz, J.P. Mohr, and L.R. Caplan

ARTICLES
971 Performance of the ABCD2 score for stroke risk post TIA: Meta-analysis and probability modeling
L.M. Sanders, V.K. Srikanth, D.J. Blacker, D.J. Jolley, K.A. Cooper, and T.G. Phan
Editorial, p. 958
981 Prevalence and significance of stroke symptoms among patients receiving maintenance dialysis
Editorial, p. 960
988 Effect of a neurohospitalist service on outcomes at an academic medical center
V.C. Douglas, B.J. Scott, G. Berg, W.D. Freeman, and S.A. Josephson
995 C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts
C. Dobson-Stone, M. Hallupp, L. Bartley, C.E. Shepherd, G.M. Halliday, P.R. Schofield, J.R. Hodges, and J.B.J. Kwok
Editorial, p. 962; see p. 1002
1002 Frontotemporal dementia due to C9ORF72 mutations: Clinical and imaging features
Editorial, p. 962; see p. 995
1012 Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD
F. Fratini, S. Principe, M. Puopolo, A. Ladogana, A. Poleggi, P. Piscopo, G. Bruno, S. Castrechini, R. Pascone, A. Confoloni, L. Minghetti, F. Cardone, M. Pocchiari, and M. Crescenzi
Editorial, p. 965
1019 Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Study
N. Cherbuin, P. Sachdev, and K.J. Anstey
1027 Lower cognitive performance in healthy G2019S LRRK2 mutation carriers
A. Thaler, A. Mirelman, T. Gurevich, E. Simon, A. Orr-Urtreger, K. Marder, S. Bressman, and N. Giladi, on behalf of the LRRK2 Ashkenazi Jewish Consortium
1033 Altered fast and slow inactivation of the N440K Na,1.4 mutant in a periodic paralysis syndrome
C. Lossin, T.-S. Nam, S. Shahangian, M.A. Rogawski, S.-Y. Choi, M.-K. Kim, and I.-N. Sunwoo
1041 Metabolic profile of PML lesions in patients with and without IRIS: An observational study
S. Gheuens, L. Ngo, X. Wang, D.C. Alsop, R.E. Lenkinski, and I.J. Korinalk

CONTINUED
1049 Recommendations for optimal ICD codes to study neurologic conditions: A systematic review

HISTORICAL NEUROLOGY
1056 Giuseppe Ferrario and the epidemiology of apoplexy during the 19th century
M.A. Riva, L. Tremolizzo, L. Cambioli, C. Ferrarese, and G. Cesana

CONTEMPORARY ISSUES IN NEUROLOGIC PRACTICE: EDUCATION
1060 Standardized sign-out improves completeness and perceived accuracy of inpatient neurology handoffs

CLINICAL/SCIENTIFIC NOTES
1065 Does natalizumab therapy worsen neuromyelitis optica?
A. Jacob, M. Hutchinson, L. Elsone, S. Kelly, R. Ali, I. Saukans, N. Tubridy, and M. Boggild

1067 The earlier, the smaller, the better for natalizumab-associated PML: In MRI vigilance veritas?

NEUROIMAGES
1070 MRI and PET imaging discordance in neurosarcoïdosis
J.F. Huang, A.J. Aksamit, and N.P. Staff

RESIDENT & FELLOW SECTION
e83 Media and Book Reviews: The Causes of Epilepsy: Common and Uncommon Causes in Adults and Children
R. Sarkis

e84 Teaching NeuroImages: Atypical Wyburn-Mason syndrome
J. Madey, R.K. Lehman, I. Chaudry, and S.L. Vaillancourt

e85 Teaching NeuroImages: CNS actinomycosis in an immunocompetent patient
N.S. Narayanan, F. Sheriff, and J.M. Boyce

e86 Teaching NeuroImages: Syntelencephaly: Middle interhemispheric fusion
A. Arora, R.K. Sahoo, and D. Srivastava

WRITE & CLICK: EDITOR’S CHOICE
1071 Total daily physical activity and the risk of AD and cognitive decline in older adults
K. Abe; Author Response: A.S. Buchman, L. Yu, P.A. Boyle, R.S. Wilson, D.A. Bennett

1071 Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial
F. Deisenhammer, H. Hegen

CORRECTION
1072 Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies

DEPARTMENT
C3 In the Next Issue of Neurology®

Podcast at www.neurology.org  CME  Video  Patient Page  LOE classification  LOE recommendation

Find Neurology® on Facebook: http://tinyurl.com/neurologyfan
Follow Neurology® on Twitter: http://twitter.com/GreenJournal

Copyright © by AAN Enterprises, Inc. Unauthorized reproduction of this article is prohibited.